• Français Français French fr
  • Nederlands Nederlands Dutch nl
  • English English English en
Airflow 3 Clinical Trial
  • ABOUT COPD
  • THE TRIAL
  • THE PROCEDURE
  • SITE LOCATIONS
  • Menu Menu

Search

Recent Comments

    Archives

      Categories

      • No categories

      Meta

      • Log in
      • Entries feed
      • Comments feed
      • WordPress.org

      Contact Us

      Common potential risks associated with the TLD procedure include, but are not limited to, worsening of COPD symptoms (shortness of breath, increased cough, COPD exacerbations), coughing up blood tinged mucous, difficulty swallowing, chest pain, upset stomach or feeling of fullness, trouble processing food, and fever.

      Nuvaira® Lung Denervation System is an investigational device in the United States and has CE mark regulatory approval in the European Economic Area (EEA).

      © 2022 Nuvaira®, Inc. All rights reserved. Privacy Terms of Use

      Scroll to top
      This website uses cookies to improve your experience. Cookie settingsACCEPT
      Privacy & Cookies Policy

      Privacy Overview

      This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are as essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
      Necessary
      Always Enabled
      Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
      SAVE & ACCEPT